Senores Pharma. Q1 FY27 Earnings Call — Analysis (NSE: SENORES)
Senores Pharma reports Q1FY27 revenue ₹180 Cr (+36% YoY) with EBITDA margin 30% (+810 bps) and guides 30-40% revenue growth, 50-60% PAT growth for FY27, aiming for ₹2,500-3,000 Cr in 3-4 years.
The take
Q1FY27 Revenue ₹180 Cr ( +36% YoY ) . New guidance — FY27 fy27 revenue growth 30% to 40% . New story: ANDA portfolio scaling and rapid commercializat… .
Results
Revenue ₹180 Cr +36% YoY; EBITDA ₹54 Cr +87% YoY; EBITDA margin 30% (+810bps); PAT ₹31 Cr +56% YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹180 Cr | +36% | yoy · Q1FY27 |
| EBITDA | ₹54 Cr | +87% | yoy · Q1FY27 |
| EBITDA margin | 30% | +810 bps | yoy · Q1FY27 |
| PAT | ₹31 Cr | +56% | yoy · Q1FY27 |
| Emerging markets operating cash flow | ₹18 Cr | point_in_time · Q1FY27 · Q1FY27 |
Guidance
FY27 revenue growth 30-40% and PAT growth 50-60%; long-term target of ₹2,500-3,000 Cr revenue in 3-4 years with similar or better margins.
What management committed to
- [Senores Pharmaceuticals] expects consolidated revenue growth of approximately 30% to 40% for FY27. — 30% to 40%, FY27
- [Senores Pharmaceuticals] expects PAT growth of approximately 50% to 60% for FY27. — 50% to 60%, FY27
- [Senores Pharmaceuticals] targets consolidated revenue of ₹2,500 Cr to ₹3,000 Cr in about three to four years with similar or slightly better profitability. — ₹2,500 Cr to ₹3,000 Cr, FY30-FY31
- [Senores Pharmaceuticals] expects emerging markets EBITDA margin of 18% to 20% for the full year FY27. — 18% to 20%, FY27
- [Zoraya] and [Amerisyn] subsidiaries will commence operations by September-October 2026. — Q2FY27-Q3FY27
- [Senores Pharmaceuticals] plans to commercialize [the] 35 [identified approved] ANDAs over the next 18 to 20 months. — 35 ANDAs, FY28
- [Senores Pharmaceuticals'] Chhatral manufacturing facility will obtain European PIC/S approval by Q2-Q3 FY27. — Q3FY27
- [Senores Pharmaceuticals] will incur ₹100-120 Cr of capex across all subsidiaries in FY27. — ₹100-120 Cr, FY27
- [Senores Pharmaceuticals'] FY28 capex run-rate will be at least ₹60-75 Cr. — minimum ₹60 Cr to ₹75 Cr, FY28
- [Senores Pharmaceuticals] expects branded generics revenue to grow 30% to 40% year-over-year in FY27. — 30% to 40%, FY27
- [Apnar] facility further capacity expansion, including third and fourth production lines, will be completed over the next 12 to 18 months. — FY28
Key themes
ANDA pipeline scaling and capacity expansion
How the narrative shifted
- ANDA portfolio scaling and rapid commercialization: Management highlights doubling of approved ANDAs to 58, with 35 launches planned in 18-20 months and every product already commercially mapped, driving regulated market growth.
- Manufacturing capacity build-out at Apnar: Apnar facility ramped to 80-90% utilization, produced 30 million units, with third and fourth lines under execution to support ANDA pipeline and CDMO growth.
- US front-end subsidiaries as next growth lever: Zoraya (own-label) and Amerisyn (government) to go live by Oct 2026, expected to “structurally advance our entire US business to multifold” over subsequent years.
- Emerging markets margin normalization and PIC/S unlock: EM margins improved vs last year Q1 to 14%, full-year target 18-20%; PIC/S approval by Q2-Q3 to open South Africa, Vietnam, adding 900+ registrations.
- Capital reallocation from sterile injectables to oral solids: IPO proceeds shifted from large greenfield injectable to oral solid capacity at Apnar and US, citing near-term ROI, while keeping a pilot injectable project.
- Tariff risk as a wait-and-watch macro factor: cautious
Operational commentary
- ANDA portfolio expanded to 58 approvals (from 30 a year ago), 23 commercialized; 35 additional ANDAs planned for commercialization over 18-20 months with commercial partners already mapped.
- Apnar USFDA facility commercialized 6 products in Q1, produced ~3 Cr units, operating at 80-90% capacity; capacity expansion with third and fourth production lines underway to support pipeline.
- US front-end subsidiaries Zoraya and Amerisyn on track to commence operations in Sep-Oct 2026, aimed at scaling B2C and government business.
- Emerging markets: Chhatral facility had PIC/S inspection, EU PIC/S approval expected by Q2-Q3 FY27, unlocking mid-tier markets like South Africa and Vietnam.
- Emerging markets turned cash flow positive, generating ₹18 Cr of operating cash in Q1.
- Capex of ₹100-120 Cr planned for FY27, focused on expanding oral solid capacities at Apnar and US, and starting a scaled-down sterile injectable pilot.
- Branded generics India segment shifting focus to profitability, targeting ₹50-60 Cr sales with 35-40% EBITDA margin while maintaining 30-40% growth.
- CDMO/CMO portfolio expanded significantly alongside own-ANDA pipeline.
Analyst Q&A
Q. What is the impact of potential US tariffs on generic medicines?
We will wait until the trade agreement between India and US is signed for clarity; the scenario is two years away and too early to worry.
Q. Can you give specific PAT growth guidance for FY28?
It's premature to give an exact number for FY28; we have given an overall guidance for the next 3-4 years.
Q. Why did emerging markets EBITDA margin decline sequentially from 20% in Q4 to 14% in Q1?
Historically H2 is stronger; Q1 has always been lower. Last year Q1 margin was single-digit, and we are confident of achieving 18-20% full-year EBITDA margin.
Research and educational content only. Not investment advice.